Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of disease biology.
The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.
Driven by world-class science and monumental funding, the UK TechBio sector is undergoing a profound paradigm shift – meet the innovative BIA members leading the charge
Cell and Gene Therapy Catapult (CGT Catapult) will provide investment to Lir Therapeutics (Lir) to accelerate the development of nAAVigator, its AI-driven AAV capsid design platform.
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.
Brainomix announces an expansion of its partnership with Boehringer Ingelheim to improve the care of patients with progressive pulmonary fibrosis (PPF).
BIA calls for coordinated action and a clear mandate for Health Data Research Service (HDRS) to prioritise UK value creation with health innovators and job creators, a key sector for economic growth
BIA’s health data vision 2035 report sets out how the UK can use consented and well-governed health data to drive economic growth, innovation and better patient outcomes.
Outpost Bio has raised $3.5 million in pre-seed funding to build frontier AI models that make human microbiology computable, enabling more precise prediction and optimization of intervention outcomes.
With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.
It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.
Our UK biotech financing 2025 report is out today, including data and commentary on how the biotech investment landscape fared last year. 2025 was a brutal year for the sector, but an upswing in deal numbers going into 2026 and recent capital injections give good reason to be optimistic.
